Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Tanner

Ophthalmology Lexington, KY Medical Doctor

NPI 1588026181 CMS profile 4223293

2720 Old Rosebud Rd Ste 110, Lexington, KY 40509

Open in the dashboard

General payments

$3,617

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Tanner of Lexington, KY is reported in the CMS Open Payments database as having received $3,617 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $177 6
2024 General $484 13
2023 General $983 23
2022 General $986 30
2021 General $719 19
2020 General $116 6
2019 General $151 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Tanner
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Michael Tanner were reported at $177. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Michael Tanner Ophthalmology median Middle half National median
2019 $151 $258 $104–$655 $163
2020 $116 $126 $45–$321 $114
2021 $719 $205 $76–$534 $132
2022 $986 $266 $100–$678 $149
2023 $983 $308 $117–$745 $160
2024 $484 $340 $127–$846 $164
2025 $177 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $2,358 67 payments
  2. Allergan Inc. $342 11 payments
  3. Genentech USA, Inc. $252 2 payments
  4. Johnson & Johnson Surgical Vision, Inc. $159 5 payments
  5. Novartis Pharmaceuticals Corporation $156 7 payments
  6. Astellas Pharma US Inc $110 1 payment
  7. Bausch & Lomb Americas Inc. $104 1 payment
  8. Oyster Point Pharma, Inc. $88 3 payments
  9. Bausch & Lomb, a division of Bausch Health US, LLC $19 1 payment
  10. Sun Pharmaceutical Industries Inc. $17 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,577 99 payments
  2. Education $40 1 payment
Products named General payments · program years 2019–2025
  1. Clareon Ophthalmology $795 25 payments
  2. AcrySof IQ PanOptix $295 6 payments
  3. VABYSMO $252 2 payments
  4. ARGOS $222 7 payments
  5. Centurion $171 2 payments
  6. XIIDRA $156 7 payments
  7. Clareon Ophthalmology $150 1 payment
  8. AcrySof IQ PanOptix UV IOL $134 7 payments
  9. Tecnis IOL $132 4 payments
  10. Luxor $118 3 payments
  11. Other $1,103 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

399

Median for Ophthalmology: 891

Drug cost

$21,688

Median for Ophthalmology: $68,233

Branded share of claims

22.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 15 $11,190
Combigan Brimonidine Tartrate/Timolol Brand 12 $4,330
Prednisolone Acetate Generic 79 $2,710
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 50 $959
Latanoprost Generic 111 $778
Ofloxacin Generic 38 $699
Brimonidine Tartrate Generic 46 $524
Ketorolac Tromethamine Generic 20 $188
Dorzolamide Hcl Generic 14 $181
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 14 $129

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$116,389

Medicare's payments for the services billed

Medicare patients

367

Average age 73

Services billed

1,427

214 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 46%
Diabetes 28%
Ischemic heart disease 21%
Depression 20%
Osteoporosis 15%
Chronic kidney disease 14%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record